Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paediatric dosimetry study of Rubidium (82Rb) chloride for PET imaging
2018-002917-36Phase 4
- Sponsor
- Jubilant DraxImage
- Start
- Sep 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rubidium-82 chloride in cardiac ischemia, sponsored by Jubilant DraxImage. Primary endpoint: Organ radiation absorbed doses.
02
Drugs
rubidium-82 chloride
03
Conditions
cardiac ischemia
Beyond the preview
Go deeper on 2018-002917-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002917-36.